PCO
MCID: PLY105
MIFTS: 45

Polycystic Ovary Syndrome 1 (PCO)

Categories: Blood diseases, Endocrine diseases, Metabolic diseases, Rare diseases, Skin diseases

Aliases & Classifications for Polycystic Ovary Syndrome 1

MalaCards integrated aliases for Polycystic Ovary Syndrome 1:

Name: Polycystic Ovary Syndrome 1 57 13
Polycystic Ovary Syndrome 73
Stein-Leventhal Syndrome 57
Steinleventhal Syndrome 76
Hyperandrogenemia 57
Pco1; Pco 57
Pcos1 57
Pco1 57
Pcos 57
Pco 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant
probably heterogeneous


HPO:

32
polycystic ovary syndrome 1:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 184700
MedGen 42 C0032460
UMLS 73 C0032460

Summaries for Polycystic Ovary Syndrome 1

MalaCards based summary : Polycystic Ovary Syndrome 1, also known as polycystic ovary syndrome, is related to ovarian cyst and perrault syndrome 1, and has symptoms including pelvic pain An important gene associated with Polycystic Ovary Syndrome 1 is PCOS1 (Polycystic Ovary Syndrome 1). The drugs Metformin and Estradiol valerate have been mentioned in the context of this disorder. Affiliated tissues include ovary, liver and heart, and related phenotypes are obesity and abnormality of metabolism/homeostasis

Wikipedia : 76 Polycystic ovary syndrome (PCOS) is a set of symptoms due to elevated androgens (male hormones) in... more...

Description from OMIM: 184700

Related Diseases for Polycystic Ovary Syndrome 1

Diseases in the Polycystic Ovary Syndrome family:

Polycystic Ovary Syndrome 1

Diseases related to Polycystic Ovary Syndrome 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Related Disease Score Top Affiliating Genes
1 ovarian cyst 11.2
2 perrault syndrome 1 11.1
3 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 11.0
4 hair-an syndrome 11.0
5 endometrial adenocarcinoma 10.6
6 adenocarcinoma 10.6
7 hyperandrogenism 10.5
8 dermoid cyst 10.4
9 ventricular fibrillation, paroxysmal familial, 1 10.3
10 anovulation 10.2
11 hyperinsulinism 10.2
12 infertility 10.2
13 body mass index quantitative trait locus 1 10.2
14 endometrial cancer 10.2
15 ovarian hyperstimulation syndrome 10.2
16 glucose intolerance 10.2
17 diabetes mellitus 10.0
18 amenorrhea 10.0
19 hypothyroidism 10.0
20 breast cancer 10.0
21 peutz-jeghers syndrome 10.0
22 progesterone resistance 10.0
23 aging 10.0
24 homocysteinemia 10.0
25 fatty liver disease, nonalcoholic 1 10.0
26 ovarian disease 10.0
27 placenta disease 10.0
28 polycystic ovary syndrome 9.9
29 acanthosis nigricans 9.9
30 alopecia, androgenetic, 1 9.9
31 schizophrenia 9.9
32 diabetes mellitus, insulin-dependent 9.9
33 insulin-like growth factor i 9.9
34 alopecia 9.9
35 androgenic alopecia 9.9
36 cortisone reductase deficiency 9.9
37 conn's syndrome 9.9
38 granulosa cell tumor of the ovary 9.9
39 precocious puberty 9.9
40 neurofibromatosis, type ii 9.8
41 arteries, anomalies of 9.8
42 hypercholesterolemia, familial 9.8
43 lipoid congenital adrenal hyperplasia 9.8
44 premature ovarian failure 1 9.8
45 bipolar disorder 9.8
46 coronary artery anomaly 9.8
47 insulinoma 9.8
48 liver disease 9.8
49 renal tubular acidosis 9.8
50 chorioamnionitis 9.8

Graphical network of the top 20 diseases related to Polycystic Ovary Syndrome 1:



Diseases related to Polycystic Ovary Syndrome 1

Symptoms & Phenotypes for Polycystic Ovary Syndrome 1

Symptoms via clinical synopsis from OMIM:

57
Growth:
obesity

Hair:
hirsutism

Misc:
response to bilateral wedge resection of the ovaries
increased frequency of early baldness or excessive hairiness in male first-degree relatives

G U:
enlarged polycystic ovaries
amenorrhea
oligomenorrhea

Endocrine:
no virilization

Lab:
normal 24-hr urinary ketosteroids
elevated dehydroepiandrosteronesulfate
increased 5-alpha-reductase activity in the liver and skin
elevated androstanedione and/or testosterone and luteinizing hormone
low estradiol and follicle-stimulating hormone levels
more

Clinical features from OMIM:

184700

Human phenotypes related to Polycystic Ovary Syndrome 1:

32 (show all 6)
# Description HPO Frequency HPO Source Accession
1 obesity 32 HP:0001513
2 abnormality of metabolism/homeostasis 32 HP:0001939
3 enlarged polycystic ovaries 32 HP:0008675
4 amenorrhea 32 HP:0000141
5 hirsutism 32 HP:0001007
6 oligomenorrhea 32 HP:0000876

UMLS symptoms related to Polycystic Ovary Syndrome 1:


pelvic pain

Drugs & Therapeutics for Polycystic Ovary Syndrome 1

Drugs for Polycystic Ovary Syndrome 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 363)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
2 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 979-32-8
3
Cyproterone Acetate Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable 427-51-0
4
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-28-2 5757
5
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-63-6 5991
6
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 28014-46-2
7
Orlistat Approved, Investigational Phase 4,Phase 2,Not Applicable 96829-58-2 3034010
8
Resveratrol Approved, Experimental, Investigational Phase 4,Phase 1,Not Applicable 501-36-0 445154
9
Simvastatin Approved Phase 4,Phase 3,Not Applicable 79902-63-9 54454
10
Ganirelix Approved Phase 4,Early Phase 1 123246-29-7, 124904-93-4 25081094
11
Drospirenone Approved Phase 4,Phase 3,Phase 1,Not Applicable 67392-87-4 68873
12
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-05-9 6006 143
13
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-83-0 5994
14
Menotropins Approved Phase 4,Phase 2,Phase 1,Not Applicable 61489-71-2, 9002-68-0 5360545
15
Hydrocortisone acetate Approved, Vet_approved Phase 4,Not Applicable,Early Phase 1 50-03-3
16
Pioglitazone Approved, Investigational Phase 4,Not Applicable,Early Phase 1 111025-46-8 4829
17
Hydrocortisone Approved, Vet_approved Phase 4,Not Applicable,Early Phase 1 50-23-7 5754
18
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 112809-51-5 3902
19
Zinc Approved, Investigational Phase 4,Early Phase 1,Not Applicable 7440-66-6
20
Acarbose Approved, Investigational Phase 4,Not Applicable 56180-94-0 441184
21
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-22-0 6013
22
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 71-58-9
23
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
24
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 616-91-1 12035
25
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
26
Leuprolide Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 53714-56-0 657181 3911
27
Liraglutide Approved Phase 4,Phase 3 204656-20-2 44147092
28
Citalopram Approved Phase 4 59729-33-8 2771
29
Racepinephrine Approved Phase 4,Not Applicable,Early Phase 1 329-65-7 838
30
Epinephrine Approved, Vet_approved Phase 4,Not Applicable,Early Phase 1 51-43-4 5816
31
Rosiglitazone Approved, Investigational Phase 4,Not Applicable 122320-73-4 77999
32
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
33
Hydroxocobalamin Approved Phase 4,Not Applicable 13422-51-0 11953898 44475014
34
Methylcobalamin Approved, Experimental, Investigational Phase 4,Not Applicable 13422-55-4
35
Alogliptin Approved Phase 4 850649-61-5 11450633
36
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
37
Tamoxifen Approved Phase 4 10540-29-1 2733526
38
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
39
Desogestrel Approved Phase 4,Phase 3 54024-22-5 40973
40
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
41
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
42
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
43
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
44
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 77-92-9 311
45
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
46
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1406-16-2
47
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 67-97-0 5280795 6221
48
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-14-6 5280793
49
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 73-31-4 896
50
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938

Interventional clinical trials:

(show top 50) (show all 604)
# Name Status NCT ID Phase Drugs
1 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4 Metformin
2 the Effect of Diane-35 Pretreatment on In-vitro Fertilization Outcome for Patients With Polycystic Ovary Syndrome Unknown status NCT01752270 Phase 4 Diane-35 pretreatment;Diane-35 pretreatment
3 The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01475019 Phase 4 Orlistat;Sibutramine
4 Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS) Unknown status NCT00378729 Phase 4 Metformin and FSHr
5 Effects of Simvastatin and Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT02766803 Phase 4 Simvastatin and micronized trans-resveratrol
6 Endometrial Scratching During Laproscopic Ovarian Drilling in Subfertile PCOS Women Unknown status NCT02140398 Phase 4
7 Strategies for Ovulation Induction in Anovulatory Infertile Patients With PCOS Unknown status NCT00461643 Phase 4 Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins
8 Metformin in Infertile PCOS Patients Unknown status NCT00501904 Phase 4 Metformin
9 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
10 PCOS, Therapy and Markers of Cardiovascular Risk Unknown status NCT01798875 Phase 4 oral metformin;oral contraceptive
11 Metformin in Step-down Regimen Versus Conventional Low Dose Step-up Protocol in Patients With PCOS Undergoing IVF Unknown status NCT01438190 Phase 4 Metformin, gonadotropins in step-down regimen;Placebo, gonadotropins in step-up regimen
12 Metformin and Gestational Diabetes in High-risk Patients: a RCTs Unknown status NCT00883259 Phase 4 Metformin
13 Adding L-carnitine in Clomiphene Resistant Polycystic Ovary Improves the Quality of Ovulation and the Pregnancy Outcome Unknown status NCT01665547 Phase 4 l-carnitine
14 Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients Unknown status NCT00417144 Phase 4 Arvekap 0.1mg (Triptorelin, Ipsen, France);Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)
15 Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants Unknown status NCT02027337 Phase 4 20 mcg ethinylestradiol /3 mg drospirenone;20 mcg ethinylestradiol/3 mg drospirenone and Selmevit;30 mcg ethinylestradiol/3 mg drospirenone;30 mcg ethinylestradiol/3 mg drospirenone and Selmevit;35 mcg ethinylestradiol/2 mg cyproterone;35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
16 Corifollitropin Alfa Application in PCOS Patients Unknown status NCT02215135 Phase 4 Corifollitropin alfa
17 Metformin for the Treatment of Unexplained Oligozspermia Unknown status NCT01529177 Phase 4 Metformin / clomid / hCG;Clomiphene citrate / hCG
18 Polycystic Ovary Syndrome - Improving Outcomes Completed NCT01504321 Phase 4 Moxonidine;Placebo
19 Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome Completed NCT00679679 Phase 4 Metformin;Placebo
20 N-acetyl Cysteine for Ovulation Induction in Clomiphene Citrate Resistant Polycystic Ovary Syndrome Completed NCT02239107 Phase 4 N-Acetyl cysteine
21 Adding L-Carnitine to Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome Completed NCT03630341 Phase 4 Clomiphene Citrate 50mg;L-carnitine;Placebo Oral Tablet
22 Trial With Metformin in Women With Polycystic Ovary Syndrome Completed NCT02280057 Phase 4 Metformin;Placebo
23 PCOSMIC Trial - PolyCystic Ovary Syndrome, Metformin for Infertility With Clomiphene Completed NCT00795808 Phase 4 Metformin;Placebo;Metformin + Clomiphene;Metformin;Clomiphene
24 The Effects of Fish Oils on Blood Pressure, Heart Rate Variability and Liver Fat in the Polycystic Ovary Syndrome Completed NCT00620529 Phase 4
25 Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome Completed NCT01118598 Phase 4 tredaptive (nicotinic acid/ laropiprant);placebo
26 Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism Completed NCT01360996 Phase 4 3 mg DRSP/20 μg EE
27 The Effect of Ethinyl Estradiol on Polycystic Ovary Syndrome Women Undergoing Intrauterine Insemination Completed NCT01219101 Phase 4 clomiphene citrate with ethinyl esteradiol;clomiphene citrate with plasebo
28 Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS) Completed NCT00805935 Phase 4 Menotropin;Progesterone vaginal insert;Follitropin beta;Progesterone in oil;leuprolide acetate
29 LIPT - Liraglutide in Polycystic Ovary Syndrome Completed NCT02073929 Phase 4 Liraglutide;placebo
30 The Effects of Vitamin D on Angiogenic Factors in Women With Polycystic Ovary Syndrome Completed NCT02460380 Phase 4 Vitamin D3
31 Metformin and Folate Supplementation in Polycystic Ovary Syndrome (PCOS) Patients Completed NCT00953355 Phase 4 Folate plus metformin;Placebo plus metformin
32 Short-term Structured Exercise Training Program Plus Diet Intervention in Patients With Polycystic Ovary Syndrome (PCOS) Completed NCT01004068 Phase 4 Clomiphene citrate
33 Ovarian Stimulation and Intrauterine Insemination in Women With Polycystic Ovarian Syndrome Completed NCT01675843 Phase 4
34 Pioglitazone Treatment in Polycystic Ovary Syndrome Completed NCT00145340 Phase 4 pioglitazone
35 Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Completed NCT01021579 Phase 4 Metformin plus Placebo;Metfomin plus Simvastatin
36 Polycystic Ovary Syndrome and Liraglutide Completed NCT01899430 Phase 4 liraglutide;metformin
37 Phytoestrogens as an Alternative to Estradiol in Ovulation Induction in PCOS Completed NCT02352597 Phase 4 phytoestrogen;estradiol valerate;clomiphene citrate
38 Metformin and Folate in Pregnant Polycystic Ovary Syndrome(PCOS) Women Completed NCT01115140 Phase 4 metformin plus placebo;Metformin plus folic acid;placebo plus folic acid;placebo alone
39 Role of Melatonin Supplementation in Follicular Fluid of in Vitro Fertilization (IVF) Patients With Polycystic Ovarian Syndrome Completed NCT01540747 Phase 4
40 Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin Completed NCT01911468 Phase 4 metformin;liraglutide;metformin and liraglutide
41 The Effect of Cipralex on Quality of Life, Adrenal Activity Glucose Metabolism, Physical and Mental Health in PCOS Completed NCT01961180 Phase 4 Cipralex;Placebo
42 PDE-4 Inhibitor Roflumilast and Polycystic Ovary Syndrome Completed NCT02037672 Phase 4 metformin;metformin and roflumilast
43 PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome Completed NCT02187250 Phase 4 metformin;liraglutide;roflumilast
44 The Effects of OCP and Metformin on Clinical, Hormonal, Metabolic and Ultrasonographic Characteristics in PCOS Completed NCT02866786 Phase 4 Metformin;ethinyl estradiol and cyproterone acetate
45 Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study Completed NCT00640224 Phase 4 rosiglitazone;drospirenone/ethinyl estradiol
46 Effects of Metformin vs Oral Contraceptives on CV Risk Markers in PCOS Completed NCT00428311 Phase 4 Metformin;Ethynyl-estradiol plus cyproterone acetate
47 Incretin Effect in PCOS Women Completed NCT01892254 Phase 4 Metformin;Placebo
48 Letrozole Versus Clomifene Citrate for Ovulation Induction Completed NCT00478504 Phase 4 Letrozole;Clomifene citrate
49 Metformin in High Responder Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF Cycles Completed NCT01233206 Phase 4 Metformin;Placebo administration
50 Metformin Suspension and Insulin Sensitivity Completed NCT00437333 Phase 4 Metformin cloridrate

Search NIH Clinical Center for Polycystic Ovary Syndrome 1

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Polycystic Ovary Syndrome 1

Anatomical Context for Polycystic Ovary Syndrome 1

MalaCards organs/tissues related to Polycystic Ovary Syndrome 1:

41
Ovary, Liver, Heart, Skin, Endothelial, Bone, Pituitary

Publications for Polycystic Ovary Syndrome 1

Articles related to Polycystic Ovary Syndrome 1:

(show top 50) (show all 809)
# Title Authors Year
1
Similarities and differences in the reproductive phenotypes of women with congenital hypogonadotrophic hypogonadism caused by GNRHR mutations and women with polycystic ovary syndrome. ( 30476149 )
2019
2
Bidirectional Mendelian randomization to explore the causal relationships between body mass index and polycystic ovary syndrome. ( 30496407 )
2019
3
Downregulation of Extracellular Matrix and Cell Adhesion Molecules in Cumulus Cells of Infertile Polycystic Ovary Syndrome Women with and without Insulin Resistance. ( 30507086 )
2019
4
Urinary concentration of personal care products and polycystic ovary syndrome: A case-control study. ( 30265948 )
2019
5
Association between The Number of Retrieved Mature Oocytes and Insulin Resistance or Sensitivity in Infertile Women with Polycystic Ovary Syndrome. ( 30291692 )
2019
6
miR-323-3p regulates the steroidogenesis and cell apoptosis in polycystic ovary syndrome (PCOS) by targeting IGF-1. ( 30300681 )
2019
7
Association between arginase-containing platelet-derived microparticles and altered plasma arginine metabolism in polycystic ovary syndrome. ( 30367832 )
2019
8
Follicular dynamics of glycerophospholipid and sphingolipid metabolisms in polycystic ovary syndrome patients. ( 30121347 )
2019
9
Long-term testosterone treatment during pregnancy does not alter insulin or glucose profile in a sheep model of polycystic ovary syndrome. ( 28851248 )
2019
10
Body image, personality profiles and alexithymia in patients with polycystic ovary syndrome (PCOS). ( 30398405 )
2018
11
Lysyl oxidase blockade ameliorates anovulation in polycystic ovary syndrome. ( 30272163 )
2018
12
Asthma severity and fertility outcome in women with polycystic ovary syndrome: a registry-based study. ( 30406126 )
2018
13
Polycystic ovary syndrome and autism: A test of the prenatal sex steroid theory. ( 30065244 )
2018
14
Clinical course of depression symptoms and predictors of enduring depression risk in women with polycystic ovary syndrome: Results of a longitudinal study. ( 30458991 )
2018
15
Endometrial injury for patients with endometriosis and polycystic ovary syndrome undergoing medically assisted reproduction: current data and a protocol. ( 30144383 )
2018
16
Pleiotropic roles of melatonin in endometriosis, recurrent spontaneous abortion, and polycystic ovary syndrome. ( 29493042 )
2018
17
Valproate-Induced Polycystic Ovary Syndrome in a Girl with Epilepsy: A Case Study. ( 30464147 )
2018
18
Polycystic ovary syndrome in familial partial lipodystrophy type 2 (FPLD2): basic and clinical aspects. ( 30131000 )
2018
19
Visceral adiposity index for the diagnosis of nonalcoholic fatty liver disease in premenopausal women with and without polycystic ovary syndrome. ( 30244768 )
2018
20
The Association of Hispanic Ethnicity with Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome. ( 30112518 )
2018
21
Analyses of risk factors for polycystic ovary syndrome complicated with non-alcoholic fatty liver disease. ( 29725371 )
2018
22
A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis. ( 29747678 )
2018
23
Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database. ( 29590099 )
2018
24
Polycystic ovary syndrome and risk factors for gestational diabetes. ( 29858213 )
2018
25
The Effect of Metformin Therapy for Preventing Gestational Diabetes Mellitus in Women with Polycystic Ovary Syndrome: A Meta-Analysis. ( 29890554 )
2018
26
Identification of microRNAs and genes associated with hyperandrogenism in the follicular fluid of women with polycystic ovary syndrome. ( 29193229 )
2018
27
Are Psychosocial Consequences of Obesity and Hyperandrogenism Present in Adolescent Girls with Polycystic Ovary Syndrome? ( 30147723 )
2018
28
Close correlation between hyperandrogenism and insulin resistance in women with polycystic ovary syndrome-Based on liquid chromatography with tandem mass spectrometry measurements. ( 30350882 )
2018
29
Idiopathic Hyperprolactinemia Presenting as Polycystic Ovary Syndrome in Identical Twin Sisters: A Case Report and Literature Review. ( 30250766 )
2018
30
Association between the prevalence of hyperuricemia and reproductive hormones in polycystic ovary syndrome. ( 30359269 )
2018
31
Subclinical Hypothyroidism in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. ( 30542323 )
2018
32
Subclinical Hypothyroidism Impact on the Characteristics of Patients with Polycystic Ovary Syndrome. A Meta-Analysis of Observational Studies. ( 30025406 )
2018
33
Clinical, Hormonal, and Metabolic Parameters in Women with Subclinical Hypothyroidism and Polycystic Ovary Syndrome: A Cross-Sectional Study. ( 29620956 )
2018
34
Subclinical hypothyroidism is not a risk factor for polycystic ovary syndrome in obese women of reproductive age. ( 29658805 )
2018
35
Serum Kisspeptin levels in unexplained infertility, polycystic ovary syndrome, and male factor infertility. ( 30328739 )
2018
36
Polycystic ovary syndrome and nephrotic syndrome. Common causes for premature cardiovascular disease? ( 29558013 )
2018
37
Polycystic Ovary Syndrome and Periodontal disease: Underlying Links- A Review. ( 29911043 )
2018
38
Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics. ( 30445140 )
2018
39
Self-reported Polycystic Ovary Syndrome is Associated with Hypertension: A Northern Finland Birth Cohort 1966 Study. ( 30445634 )
2018
40
A randomized controlled trial comparing lifestyle intervention to letrozole for ovulation in women with polycystic ovary syndrome: a study protocol. ( 30445999 )
2018
41
Abnormal expressions of ADAMTS-1, ADAMTS-9 and progesterone receptors are associated with lower oocyte maturation in women with polycystic ovary syndrome. ( 30446843 )
2018
42
Dietary intake, body composition and metabolic parameters in women with polycystic ovary syndrome. ( 30449604 )
2018
43
The Importance of Sleep Hygiene in Polycystic Ovary Syndrome from the View of Iranian Traditional Medicine and Modern Medicine. ( 30450170 )
2018
44
Translation and implementation of the Australian-led PCOS guideline: clinical summary and translation resources from the International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. ( 30453865 )
2018
45
Correction to: Metformin improved health-related quality of life in ethnic Chinese women with polycystic ovary syndrome. ( 30453962 )
2018
46
Body mass index and basal androstenedione are independent risk factors for miscarriage in polycystic ovary syndrome. ( 30454060 )
2018
47
Geographical Prevalence of Polycystic Ovary Syndrome as Determined by Region and Race/Ethnicity. ( 30463276 )
2018
48
Total flavonoids extracted from Nervilia Fordii function  in the treatment of polycystic ovary syndrome through IL-6 mediated JAK2/STAT3 signaling pathway. ( 30463907 )
2018
49
The correlation between the concentration of hepcidin in serum and the occurrence of insulin resistance and hyperandrogenemia in women with polycystic ovary syndrome. ( 30468484 )
2018
50
Elevation of antimüllerian hormone in women with polycystic ovary syndrome undergoing assisted reproduction: effect of insulin. ( 30477916 )
2018

Variations for Polycystic Ovary Syndrome 1

Expression for Polycystic Ovary Syndrome 1

Search GEO for disease gene expression data for Polycystic Ovary Syndrome 1.

Pathways for Polycystic Ovary Syndrome 1

GO Terms for Polycystic Ovary Syndrome 1

Sources for Polycystic Ovary Syndrome 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....